Features of influenza virus hemagglutinin genes and their recoding possibilities
- 作者: Kharchenko E.P.1
-
隶属关系:
- Sechenov Institute of Evolutionary Physiology and Biochemistry of the Russian Academy of Sciences
- 期: 卷 14, 编号 4 (2024)
- 页面: 709-718
- 栏目: ORIGINAL ARTICLES
- URL: https://journal-vniispk.ru/2220-7619/article/view/268704
- DOI: https://doi.org/10.15789/2220-7619-FOA-17578
- ID: 268704
如何引用文章
全文:
详细
The world has already entered the stage of increasing odds for a new pandemic, which prompts to seek out for new flu vaccines, because existing vaccines demonstrate only suboptimal effectiveness. With the Covid-19 pandemic, the possibility of using mRNA vaccines has been opened up, and a prospect of finding hemagglutinin (HA) gene mRNA-based new influenza vaccines seems very attractive. As a rule, the mRNA vaccine is a product of recoding, which ensures the mRNA stability. However, the results of mRNA recoding can be ambiguous. The purpose of this report is to analyze the features of genes and proteins and to consider opportunities and limitations in their recoding. Primary structures of NA proteins and relevant genes were retrieved from Internet publicly available databases. The amino acid composition and frequency of dipeptides, nucleotide and dinucleotide compositions, %GC, translational code and compositions of neighboring di- and tricodones, distribution along primary structure for explicit and synonymous mutations were determined. H1N1 and H3N2 subtypes have both specific and general features (limitations) in their genes, differing not only in the number of protein substitutions, but also in the number and distribution of gene synonymous codons, which do not manifest in the protein primary structure, but appear, apparently, as a hidden factor, which causes the low effectiveness of classical influenza vaccines. The identification of several limitations in gene structure suggests that its any modification (in any gene) must not contradict each of the restrictions established by nature. The frequency of CpG dinucleotides in all studied strains is low, but a potential for optimizing it in H1N1 strains due to the prohibition of the quartet in the gene for arginine-encoding codons is especially limited and can be implemented through synonymous codons of other amino acids (alanine, proline, threonine or serine). Compared to the H1N1 subtype, the H3N2 subtype can be expected to have more possibilities in constructing stable NA gene mRNA.
作者简介
Eugene Kharchenko
Sechenov Institute of Evolutionary Physiology and Biochemistry of the Russian Academy of Sciences
编辑信件的主要联系方式.
Email: neuro.children@mail.ru
DSc (Biology), Senior Researcher
俄罗斯联邦, St. Petersburg参考
- Харченко Е.П. Поиски универсальной противогриппозной вакцины: возможности и ограничения // Эпидемиология и вакцинопрофилактика. 2019. Т. 18, № 5. C. 70–84. [Kharchenko E.P. The search for a universal influenza vaccine: possibilities and limitations. Epidemiologiya i vaktsinoprofilaktika = Epidemiology and Vaccine Prevention, 2019, vol. 18, no. 5, pp. 70–84. (In Russ.)] doi: 10.31631/2073-3046-2019-18-5-70-84
- Харченко Е.П. Проблемы и коллизии вакцинологии // Эпидемиология и вакцинопрофилактика. 2023. Т. 22, № 6. С. 183–200. [Kharchenko E.P. Problems and Collisions of Vaccinology. Epidemiologiya i vaktsinoprofilaktika = Epidemiology and Vaccine Prevention, 2023, vol. 22, no. 6, pp. 183–200. (In Russ.)] doi: 10.31631/2073-3046-2023-22-6-183-200
- Altmann D.M., Boyton R.J. COVID-19 vaccination: the road ahead. Science., 2022, vol. 375, no. 6585, pp. 1127–1132. doi: 10.1126/science.abn1755
- Erbelding E.J., Post D.J., Stemmy E.J., Roberts P.C., Augustine A.D., Ferguson S., Paules C.I., Graham B.S., Fauci A.S. A universal influenza vaccine: the strategic plan for the National Institute of Allergy and Infectious Diseases. J. Infect. Dis., 2018, vol. 218, no. 3, pp. 347–354. doi: 10.1093/infdis/jiy103
- Global influenza strategy 2019–2030. World Health Organization. URL: https://www.who.int/publications/i/item/978924151532015
- Gonçalves-Carneiro D., Bieniasz P.D. Mechanisms of attenuation by genetic recoding of viruses. mBio, 2021, vol. 12, no. 1: e02238-20. doi: 10.1128/mBio.02238-20
- Knyazev S., Chhugani K., Sarwal V., Ayyala R., Singh H., Karthikeyan S., Deshpande D., Baykal P.I., Comarova Z., Lu A., Porozov Y., Vasylyeva T.I., Wertheim J.O., Tierney B.T., Chiu C.Y., Sun R., Wu A., Abedalthagafi M.S., Pak V.M., Nagaraj S.H., Smith A.L., Skums P., Pasaniuc B., Komissarov A., Mason C.E., Bortz E., Lemey P., Kondrashov F., Beerenwinkel N., Lam T.T., Wu N.C., Zelikovsky A., Knight R., Crandall K.A., Mangul S. Unlocking capacities of genomics for the COVID-19 response and future pandemics. Nat. Methods, 2022, vol. 19, no. 4, pp. 374–380. doi: 10.1038/s41592-022-01444-z
- Komar A.A. [Synonymous codon usage — a guide for co-translational protein folding in the cell]. Mol. Biol. (Mosk.), 2019, vol. 53, no. 6, pp. 883–898. doi: 10.1134/S0026898419060090
- Lin B.C., Kaissarian N.M., Kimchi-Sarfaty C. Implementing computational methods in tandem with synonymous gene recoding for therapeutic development. Trends Pharmacol. Sci., 2023, vol. 44, no. 2, pp. 73–84. doi: 10.1016/j.tips.2022.09.008
- Martínez M.A., Jordan-Paiz A., Franco S., Nevot M. Synonymous virus genome recoding as a tool to impact viral fitness. Trends Microbiol., 2016, vol. 24, no. 2, pp. 134–147. doi: 10.1016/j.tim.2015.11.002
- Morens D.M., Taubenberger J.K., Fauci A.S. Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses. Cell. Host Microbe, 2023, vol. 31, no. 1, pp. 146–157. doi: 10.1016/j.chom.2022.11.016
- Ostrov N., Nyerges A., Chiappino-Pepe A., Rudolph A., Baas-Thomas M., Church G.M. Synthetic genomes with altered genetic codes. Curr. Opin. Syst. Biol., 2020, vol. 24, pp. 32–40. doi: 10.1016/j.coisb.2020.09.007
- Tian Y., Deng Z., Yang P. mRNA vaccines: A novel weapon to control infectious diseases. Front. Microbiol., 2022, no. 13: 1008684. doi: 10.3389/fmicb.2022.1008684
- Yang L., Tang L., Zhang M., Liu C. Recent advances in the molecular design and delivery technology of mRNA for vaccination against infectious diseases. Front. Immunol., 2022, no. 13: 896958. doi: 10.3389/fimmu.2022.896958
补充文件
